Isis Oral TNF-Alpha Inhibitor For Rheumatoid Arthritis To Enter Phase II
This article was originally published in Pharmaceutical Approvals Monthly
Isis is ramping up efforts to develop an oral tumor necrosis factor alpha inhibitor for rheumatoid arthritis, with plans to begin a Phase II trial of its oral anti-TNF antisense agent ISIS 104838 in mid-2005.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class